GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2006

Eli Lilly Amends Acquisition Price for ICOS to $2.3B

  • Eli Lilly and Company reached an agreement with ICOS to amend the merger agreement relating to the proposed acquisition of ICOS by Lilly. Under the revised terms, Lilly will acquire all of the outstanding shares of ICOS common stock at a price of $34 per share, for a total purchase price of approximately $2.3 billion.

    he proposed $34 price reflects a $2 per share increase from the $32 per share of the original merger agreement, and Lilly is affirming that this is its best and final offer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »